Massachusetts is currently home to 3224 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
NCT06719141
Recruiting
This (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DEE. The study consists of 3 main phases: Screening, Titration period, Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 24 months.
Gender:
ALL
Ages:
Between 2 years and 65 years
Trial Updated:
07/08/2025
Locations: Site Number - USA30, Boston, Massachusetts
Conditions: Developmental and Epileptic Encephalopathy
Register for Updates
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
NCT06685835
Recruiting
The primary purpose of the study is evaluate the effect of brensocatib compared with placebo.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/08/2025
Locations: USA017, Boston, Massachusetts
Conditions: Hidradenitis Suppurativa
Register for Updates
FORWARD CAD IDE Study
NCT06662500
Recruiting
The FORWARD CAD IDE Study is a Prospective, Multicenter, Single-Arm, Investigational Device Exemption (IDE) Study conducted to assess the safety and effectiveness of the Shockwave Intravascular Lithotripsy (IVL) System with the Javelin Coronary IVL Catheter for the treatment of calcified, stenotic de novo coronary artery lesions prior to stenting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Coronary Arterial Disease (CAD)
Register for Updates
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT06660394
Recruiting
This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. The total duration of the study will be approximately 24 months.
Gender:
ALL
Ages:
Between 2 years and 65 years
Trial Updated:
07/08/2025
Locations: Site Number - USA40, Boston, Massachusetts
Conditions: Dravet Syndrome
Register for Updates
Streamlined Treatment of Pulmonary Exacerbations in Pediatrics
NCT06654752
Recruiting
The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.
Gender:
ALL
Ages:
Between 3 years and 18 years
Trial Updated:
07/08/2025
Locations: Boston Children's Hospital & Harvard University, Boston, Massachusetts
Conditions: Cystic Fibrosis
Register for Updates
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
NCT06630234
Recruiting
The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). Participants will be treated in 28-day treatment cycles with an estimated duration of up to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Gastrointestinal Stromal Tumor (GIST)
Register for Updates
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
NCT06624670
Recruiting
The purpose of this study is to find out whether a medicine called spesolimab helps people with pyoderma gangrenosum (PG). The main aim is to see whether spesolimab leads to closure of PG ulcers. This study is open to adults with ulcerative PG with at least 1 ulcer that measures between 5 cm\^2 to 80 cm\^2 in size. This study has 2 parts. In Part 1, participants are put into groups randomly, which means by chance. 1 group gets spesolimab and the other group gets placebo. Placebo injections look... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Pyoderma Gangrenosum
Register for Updates
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
NCT06585410
Recruiting
This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a protein called programmed cell death-1 (PD-1) on the surface of certain immune cells. The main purpose of this study is to compare how well cemiplimab works compared to surgery, when injected into the lesion. The study is looking at: * The side effects cemip... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: University Skin Oncologists Inc, Beverly, Massachusetts
Conditions: Cutaneous Squamous Cell Carcinoma (CSCC)
Register for Updates
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT06492616
Recruiting
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Breast Cancer
Register for Updates
GF-NOURISH (Gluten Free Nutrition Optimization Through Ultra-processed Food Reduction and Improved Strategies for Health)
NCT06356220
Recruiting
The investigators propose the Gluten Free Nutrition Optimization through Ultra-processed food Reduction and Improved Strategies for Health (GF-NOURISH) study to demonstrate the feasibility and success of a nutritional education program focused on naturally occurring gluten-free foods and minimizing ultra-processed gluten-free foods. The investigators hypothesize that nutritional educational (GF-NOURISH) intervention will have multiple health benefits
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
07/08/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Celiac Disease in Children, Nutrition Disorder, Child
Register for Updates
Deprescribing in Patients Living With Dementia With Caregiver and Provider Nudges
NCT06347172
Recruiting
The objectives of this study are to demonstrate the feasibility of implementing a deprescribing nudge intervention using pragmatic methods, confirm that outcomes can be feasibly measured and evaluated at scale in a subsequent embedded pragmatic clinical trial (ePCT), and explore representativeness of persons living with dementia and care partners identified.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/08/2025
Locations: Mass General Brigham, Boston, Massachusetts
Conditions: Alzheimer Disease, Mild Cognitive Impairment, Dementia
Register for Updates
The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation.
NCT06324201
Recruiting
Observational, multi-center, non-randomized, post-market study. This is a nested sub-study of the REAL AF Registry. Consecutive symptomatic drug refractory paroxysmal atrial fibrillation (PAF) patients from the registry will be screened for enrollment to this sub-study per inclusion and exclusion criteria.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: The Brigham and Womens Hospital, Boston, Massachusetts
Conditions: Paroxysmal Atrial Fibrillation
Register for Updates